Keen interest in FcRn biology has been boosted by the findings demonstrating that blocking IgG binding to FcRn results in beneficial therapeutic effects in IgG-mediated autoimmune diseases, such as MG, CIDP and ITP (19–21). Here, FCGRT is linked to myasthenia gravis.